SG11201802932VA - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use - Google Patents
N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of useInfo
- Publication number
- SG11201802932VA SG11201802932VA SG11201802932VA SG11201802932VA SG11201802932VA SG 11201802932V A SG11201802932V A SG 11201802932VA SG 11201802932V A SG11201802932V A SG 11201802932VA SG 11201802932V A SG11201802932V A SG 11201802932VA SG 11201802932V A SG11201802932V A SG 11201802932VA
- Authority
- SG
- Singapore
- Prior art keywords
- sulfonylated
- carboxamides
- pyrazolo
- pyridin
- sulfonylated pyrazolo
- Prior art date
Links
- JKFBIZUZFKODCG-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine-6-carboxamide Chemical class N1C(C(=O)N)=CC=C2C=NN=C21 JKFBIZUZFKODCG-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239647P | 2015-10-09 | 2015-10-09 | |
| US201662309794P | 2016-03-17 | 2016-03-17 | |
| PCT/IB2016/056029 WO2017060874A1 (en) | 2015-10-09 | 2016-10-07 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201802932VA true SG11201802932VA (en) | 2018-05-30 |
Family
ID=57209654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201802932VA SG11201802932VA (en) | 2015-10-09 | 2016-10-07 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US9890158B2 (https=) |
| EP (1) | EP3359541B1 (https=) |
| JP (1) | JP6779992B2 (https=) |
| KR (1) | KR20180083323A (https=) |
| CN (1) | CN108513574B (https=) |
| AU (1) | AU2016333856C1 (https=) |
| BR (1) | BR112018007161B1 (https=) |
| CA (1) | CA3001096A1 (https=) |
| CL (1) | CL2018000911A1 (https=) |
| CO (1) | CO2018003716A2 (https=) |
| CR (1) | CR20180215A (https=) |
| CY (1) | CY1123545T1 (https=) |
| DK (1) | DK3359541T3 (https=) |
| EC (1) | ECSP18032223A (https=) |
| ES (1) | ES2829636T3 (https=) |
| HR (1) | HRP20201618T1 (https=) |
| HU (1) | HUE051067T2 (https=) |
| IL (1) | IL258553A (https=) |
| LT (1) | LT3359541T (https=) |
| MX (1) | MX379276B (https=) |
| NZ (1) | NZ741223A (https=) |
| PE (1) | PE20181348A1 (https=) |
| PH (1) | PH12018500765B1 (https=) |
| PL (1) | PL3359541T3 (https=) |
| PT (1) | PT3359541T (https=) |
| RU (1) | RU2724345C2 (https=) |
| SG (1) | SG11201802932VA (https=) |
| SI (1) | SI3359541T1 (https=) |
| TW (1) | TWI720032B (https=) |
| UY (1) | UY36943A (https=) |
| WO (1) | WO2017060874A1 (https=) |
| ZA (1) | ZA201802976B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59111B1 (sr) | 2014-08-21 | 2019-09-30 | Boehringer Ingelheim Int | Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori |
| RU2724345C2 (ru) * | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| KR20240158360A (ko) | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| GB201905711D0 (en) * | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CN114761383A (zh) * | 2019-06-12 | 2022-07-15 | 诺瑟拉有限公司 | 磺酰胺衍生物及其用途 |
| TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
| WO2021028323A1 (en) * | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| PH12022551119A1 (en) | 2019-12-10 | 2023-08-23 | Hoffmann La Roche | New methylquinazolinone derivatives |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4161933A1 (en) | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| KR20230052954A (ko) | 2020-08-20 | 2023-04-20 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022150173A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2022150174A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| JP2025505577A (ja) | 2022-02-03 | 2025-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | （６ａ，１２ａ）－１７－アミノ－１２－メチル－６，１５－ビス（トリフルオロメチル）－１３，１９－ジオキサ－３，４，１８－トリアザトリシクロ［１２．３．１．１２，５］ノナデカ－１（１８），２，４，１４，１６－ペンタエン－６－オールの調製方法及び結晶形態 |
| IL314449A (en) | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4525858A1 (en) | 2022-05-16 | 2025-03-26 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN115806532A (zh) * | 2022-08-31 | 2023-03-17 | 大连百傲化学股份有限公司 | 一种mit中杂质的制备方法 |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| CN115960100B (zh) * | 2022-12-28 | 2023-08-18 | 北京康立生医药技术开发有限公司 | 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833598A (en) * | 1972-12-29 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US20080275078A1 (en) * | 2004-03-16 | 2008-11-06 | Glaxo Group Limited | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| DE602005011286D1 (en) * | 2004-07-05 | 2009-01-08 | Astellas Pharma Inc | Pyrazolopyridinderivate |
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| WO2008147952A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA2705303A1 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| CL2008003651A1 (es) | 2007-12-10 | 2009-06-19 | Novartis Ag | Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias. |
| JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| PT2358680E (pt) | 2008-10-23 | 2013-05-14 | Vertex Pharma | Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| PL2616444T3 (pl) * | 2010-09-14 | 2016-04-29 | Inst Biochemii I Biofizyki Pan | Związki będące modulatorami zmutowanego białka CFTR oraz ich zastosowanie w leczeniu chorób związanych z zaburzeniami w funkcjonowaniu białka CFTR |
| DK2624695T3 (en) | 2010-10-08 | 2016-01-04 | Nivalis Therapeutics Inc | NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| EP2760463B1 (en) | 2011-09-20 | 2018-11-21 | The University of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
| US9630929B2 (en) * | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| AU2013348018A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| EP2994463B1 (en) | 2013-05-07 | 2017-10-25 | Galapagos NV | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| HUE040366T2 (hu) | 2013-08-08 | 2019-03-28 | Galapagos Nv | CFTR modulátor tieno[2,3-c]piránok |
| US9452986B2 (en) * | 2014-02-06 | 2016-09-27 | Abbvie Inc. | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use |
| CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| MX366556B (es) | 2014-10-31 | 2019-07-12 | Abbvie Sarl | Cromanos sustituidos y metodo de uso. |
| JP6615213B2 (ja) | 2014-10-31 | 2019-12-04 | アッヴィ・エス・ア・エール・エル | 置換テトラヒドロピランおよび使用方法 |
| US10130622B2 (en) * | 2015-10-09 | 2018-11-20 | Abbvie S.Á.R.L. | Compounds for treatment of cystic fibrosis |
| RU2724345C2 (ru) * | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
-
2016
- 2016-10-07 RU RU2018115722A patent/RU2724345C2/ru active
- 2016-10-07 PT PT167882323T patent/PT3359541T/pt unknown
- 2016-10-07 BR BR112018007161-7A patent/BR112018007161B1/pt active IP Right Grant
- 2016-10-07 PE PE2018000521A patent/PE20181348A1/es unknown
- 2016-10-07 AU AU2016333856A patent/AU2016333856C1/en not_active Ceased
- 2016-10-07 DK DK16788232.3T patent/DK3359541T3/da active
- 2016-10-07 CA CA3001096A patent/CA3001096A1/en active Pending
- 2016-10-07 WO PCT/IB2016/056029 patent/WO2017060874A1/en not_active Ceased
- 2016-10-07 LT LTEP16788232.3T patent/LT3359541T/lt unknown
- 2016-10-07 SG SG11201802932VA patent/SG11201802932VA/en unknown
- 2016-10-07 HU HUE16788232A patent/HUE051067T2/hu unknown
- 2016-10-07 PL PL16788232T patent/PL3359541T3/pl unknown
- 2016-10-07 MX MX2018004359A patent/MX379276B/es unknown
- 2016-10-07 US US15/287,911 patent/US9890158B2/en not_active Expired - Fee Related
- 2016-10-07 NZ NZ741223A patent/NZ741223A/en unknown
- 2016-10-07 CR CR20180215A patent/CR20180215A/es unknown
- 2016-10-07 KR KR1020187012937A patent/KR20180083323A/ko not_active Ceased
- 2016-10-07 HR HRP20201618TT patent/HRP20201618T1/hr unknown
- 2016-10-07 ES ES16788232T patent/ES2829636T3/es active Active
- 2016-10-07 TW TW105132676A patent/TWI720032B/zh not_active IP Right Cessation
- 2016-10-07 SI SI201630965T patent/SI3359541T1/sl unknown
- 2016-10-07 CN CN201680069459.4A patent/CN108513574B/zh active Active
- 2016-10-07 JP JP2018517444A patent/JP6779992B2/ja active Active
- 2016-10-07 EP EP16788232.3A patent/EP3359541B1/en active Active
- 2016-10-11 UY UY0001036943A patent/UY36943A/es not_active Application Discontinuation
-
2017
- 2017-12-15 US US15/843,917 patent/US10259810B2/en active Active
-
2018
- 2018-04-06 CO CONC2018/0003716A patent/CO2018003716A2/es unknown
- 2018-04-06 PH PH12018500765A patent/PH12018500765B1/en unknown
- 2018-04-08 IL IL258553A patent/IL258553A/en active IP Right Grant
- 2018-04-09 CL CL2018000911A patent/CL2018000911A1/es unknown
- 2018-04-26 EC ECIEPI201832223A patent/ECSP18032223A/es unknown
- 2018-05-07 ZA ZA2018/02976A patent/ZA201802976B/en unknown
-
2019
- 2019-03-06 US US16/293,973 patent/US20190202823A1/en not_active Abandoned
- 2019-06-18 US US16/444,495 patent/US10647717B2/en active Active
-
2020
- 2020-11-03 CY CY20201101034T patent/CY1123545T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802976B (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| IL266596A (en) | Causes, uses and methods of treating synovialitis | |
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL253284B (en) | History of 4h-pyrrolo[2,3-c]pyridine-4-one | |
| SI3134403T1 (sl) | Spojine 1H-pirolo(2,3-c)piridin-7(6H)-on in spojine pirazolo(3,4-C)priridin-7(6H)-on, kot inhibitorji proteinov BET | |
| IL251164A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
| PL3373910T3 (pl) | Preparat echinomycyny, sposób wytwarzania i sposób stosowania | |
| PL3360863T3 (pl) | Pochodna i związek pośredni etomidatu, sposób przygotowania i zastosowanie | |
| SG11201803485UA (en) | Method for producing silazane-siloxane copolymers and the use of such copolymers | |
| SG11201610266RA (en) | Choux pastry and method for producing the same | |
| GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
| IL251166A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
| EP3381921A4 (en) | GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
| HK40013476A (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| ZA201704727B (en) | New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer | |
| GB201601047D0 (en) | New process, use and method | |
| IL235077A0 (en) | New derivatives of thiochromano[2,3-c]quino lin-12-one, its preparation method and application | |
| SG10201406318YA (en) | Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof |